Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Other Accumulated Expenses: 2020-2025

Historic Other Accumulated Expenses for Janux Therapeutics (JANX) over the last 5 years, with Sep 2025 value amounting to $551,000.

  • Janux Therapeutics' Other Accumulated Expenses fell 29.18% to $551,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $551,000, marking a year-over-year decrease of 29.18%. This contributed to the annual value of $918,000 for FY2024, which is 67.21% up from last year.
  • Janux Therapeutics' Other Accumulated Expenses amounted to $551,000 in Q3 2025, which was down 6.13% from $587,000 recorded in Q2 2025.
  • In the past 5 years, Janux Therapeutics' Other Accumulated Expenses ranged from a high of $1.0 million in Q2 2023 and a low of $199,000 during Q2 2021.
  • For the 3-year period, Janux Therapeutics' Other Accumulated Expenses averaged around $745,091, with its median value being $734,000 (2023).
  • As far as peak fluctuations go, Janux Therapeutics' Other Accumulated Expenses soared by 194.52% in 2023, and later dropped by 29.75% in 2024.
  • Quarterly analysis of 5 years shows Janux Therapeutics' Other Accumulated Expenses stood at $478,000 in 2021, then skyrocketed by 30.33% to $623,000 in 2022, then fell by 11.88% to $549,000 in 2023, then soared by 67.21% to $918,000 in 2024, then declined by 29.18% to $551,000 in 2025.
  • Its Other Accumulated Expenses was $551,000 in Q3 2025, compared to $587,000 in Q2 2025 and $925,000 in Q1 2025.